A leading large biotech company engaged Certara to manage and streamline the development and annual updates of up to 15 Investigator’s Brochures (IBs) — critical regulatory documents summarizing clinical and nonclinical data for investigational drugs. Certara’s dedicated project manager introduced centralized oversight, real-time dashboards, and optimized workflows, resulting in improved team alignment, reduced delays, and enhanced submission readiness.
Oncology, Rare Diseases, Immunology, Infectious Disease
"Afton is proactive, engaged… the annual IB update process is much more manageable due to her ongoing support"
FAQs
What challenges do large biotech companies face in managing multiple Investigator's Brochure’s (IB)?
1. What challenges do large biotech companies face in managing multiple Investigator’s Brochure’s (IB)?
How did Certara help this large biotech improve Investigator's Brochure (IB) management?
Certara provided dedicated project management support, centralizing oversight for up to 15 IBs, implementing real-time dashboards, streamlining workflows, and leading cross-functional coordination. This approach improved team alignment, reduced submission delays, and strengthened regulatory readiness.
What tools and processes were implemented to streamline Investigator's Brochure (IB) updates?
What tools and processes were implemented to streamline Investigator’s Brochure (IB) updates?
What was the impact of Certara’s project management expertise on Investigator's Brochure (IB) submissions?
The client experienced fewer submission delays, greater clarity in roles and responsibilities, improved communication of risks, and higher team productivity. Certara’s success also led to expanded responsibilities, including oversight of nonclinical Development Safety Update Reports (DSURs).
Which therapeutic areas did this project cover?
The IBs supported investigational drugs in oncology, rare diseases, immunology, and infectious diseases, reflecting the client’s diverse development pipeline.
At which stages of drug development can project management for regulatory documents add value?
At which stages of drug development can project management for regulatory documents add value?
How does improved Investigator's Brochure (IB) management reduce regulatory risk?
By centralizing oversight, standardizing workflows, and tracking progress in real-time, companies can identify potential issues early, address them proactively, and meet submission deadlines with greater confidence, reducing the chance of regulatory delays.
Contact us